IDYA•benzinga•
Ideaya Biosciences Initiated Phase 1/2 Expansion In The Clinical Trial Evaluating IDE397 In Combination With Gilead's Trodelvy In Methylthioadenosine Phosphorylase-deletion Urothelial Cancer Based On Preliminary Safety And Clinical Efficacy Data
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga